Reciprocal competition binding assays have previously demonstrated that 20 of 24 human rhinovirus serotypes tested compete for a single cellular receptor. These studies suggested that the vast majority of rhinovirus serotypes utilize a single cellular receptor. With HeLa cells as an immunogen, a mouse monoclonal antibody was isolated which had the precise specificity predicted by the competition binding study. (3, 16) . We now report the isolation of a mouse monoclonal antibody which is effective in specifically blocking the attachment and subsequent infection of 78 serotypes of HRV.
The human rhinoviruses (HRVs) represent a subgroup of picornaviruses and contain over 100 antigenically distinct serotypes (4, 15) . They are of particular medical importance because they have been identified as the major causative agent of the common cold in humans (10) . Similar to other viruses, HRVs attach to specific receptor sites located on the surface of cellular membranes as a prerequisite to entry into susceptible cells (2, (5) (6) (7) 21) . Previous studies have clearly demonstrated that different groups of picornaviruses utilize different cellular receptors for attachment and entry (5, (11) (12) (13) (14) . Using competition binding assays, Lonberg-Holm et al. suggested that HRVs could be divided into at least two receptor families which did not compete with poliovirus, coxsackievirus B or adenovirus for attachment to cellular receptors (12) . They also found that one HRV family would compete with coxsackievirus A21 for a single receptor. Since this study dealt with a limited number of HRV serotypes, we expanded the study to include 24 randomly selected serotypes. Results of reciprocal competition binding studies indicated the existence of only two HRV receptor families (1) . However, 20 of the 24 HRV serotypes tested competed for a single receptor referred to as the major HRV receptor group, and only 4 of the 24 fell into a second, minor HRV receptor group. These results implied that a single cellular receptor existed on cell membranes which is utilized by the vast number of HRV serotypes. Recently, monoclonal antibodies have been isolated which specifically block poliovirus and coxsackievirus B attachment (3, 16) . We now report the isolation of a mouse monoclonal antibody which is effective in specifically blocking the attachment and subsequent infection of 78 serotypes of HRV. MATERIALS and HRVs have been previously described (1) . The cell lines listed in Table 2 were obtained from the American Type Culture Collection or the Merck cell collection and grown as described in the American Type Culture Collection instructions. In most cases, the various virus inocula consisted of infected cell supernatants that had been precleared of cellular debris by low-speed centrifugation and concentrated by polyethylene glycol precipitation. Inoculum titers were determined by plaque assay (HRVs) HRVs utilize unique cellular receptors that are different from those used by other picornaviruses, with the exception of group A coxsackieviruses (11) (12) (13) . To further demonstrate receptor antibody specificity, cell protection studies were performed by using several picornaviruses and a variety of other RNA and DNA viruses. Only the group A coxsackievirus infections of HeLa cells were blocked by the receptor Convinced that the receptor antibody had the precise specificity desired, we expanded our HRV collection to 88 serotypes and assayed each against the receptor antibody block to confirm our previous prediction that over 80% of HRVs would utilize a single receptor. The results of this extensive binding study illustrated that 78 of the 88 HRV serotypes (HRV-3 through -28, -32 through -43, -45, -46, -48, -50 through -52, -54 through -61, -63 through -81, -83 through -86, -88, and -89; and HRV-Hanks) tested share a single cellular receptor. Six new HRV serotypes (HRV-1B, -29 through -31, -47, and -62) were found which were not inhibited in the presence of receptor antibody. To rule out the possibility of a third HRV receptor group, we used the six newly determined minor HRV serotypes in competition binding assays against HRV-2. These viruses competed with HRV-2 for a single receptor site that was clearly different from that used by the major group of HRVs (Table 3) . Previous work had suggested that the minor HRV serotypes were also capable of binding to mouse cells (1, 20) . As a further demonstration that the six new serotypes that were not blocked by the receptor antibody belonged to the minor HRV group, binding studies were conducted on mouse 3T3 cells. All six could bind as well to mouse 3T3 cells as HRV-1A and HRV-2 (Table 3) . HRV-15, which belongs to the major HRV group, was unable to bind to mouse cells and served as a control.
Characterization of the receptor antibody. To further study the interaction of virus and cellular receptor, a membrane binding assay was developed. The advantages of using membranes instead of cells is that the assay can be standardized, day-to-day variations of tissue culture are eliminated, 3-day incubation at 34°C, agar overlays were removed, and plates were stained to visualize plaques. (Fig. 2) . The differences observed between HRV-14 and HRV-15 most likely reflect differences in the binding efficiency between the viruses (see below).
Repeated attempts to block receptor antibody attachment with saturating amounts of HRV-15 failed to effectively inhibit antibody attachment (data not shown). We believe that this is due to the greater avidity of the antibody for the receptor. To test this hypothesis, [35S]methionine-labeled HRV-2, HRV-14, and HRV-15 were bound to membranes. Unbound virions were removed by repeated washings of pelleted membrane-virus complex. The membrane-virus complexes were then incubated with increasing quantities of purified receptor antibody, and the release of radiolabeled virus was measured. The antibody was capable of releasing nearly 90% of HRV-14, a weak binding serotype, and 30% of HRV-15, a strong binding serotype (Fig. 3) . HRV-2, which served as a control, belongs to the minor group of HRVs and showed no release of virus from the membrane complex. Receptor antibody-mediated release of bound HRVs. Membrane-virus complexes were prepared by incubation of 960 ,ug of crude membranes with 35S-labeled HRVs (5 x 104 cpm) for 1 h at 25°C in a total volume of 0.14 ml. The membrane-virus complexes were then separated from unattached virus by pelleting (12,000 x g for 2 min) and washing with PBS. The final membrane-receptor pellets were suspended in 130 ,ul of PBS and distributed into six tubes. Purified receptor antibody was added to each of the tubes as indicated, and the tubes were incubated at 25°C for 1 h. The membranes were then pelleted, and the amount of radiolabeled HRV-14 (0), HRV-15 (Li), and HRV-2 (A) that was still associated with the membranes was determined.
demonstrates that HRVs do not infect neighboring cells by any mechanism except receptor-mediated entry.
DISCUSSION
Traditional approaches to controlling HRV infections do not appear to be feasible, since there is a vast number of antigenically distinct serotypes. A greater understanding of the structural and molecular characteristics of these viruses will be necessary for the design of novel anti-HRV agents.
Of particular importance will be the discovery of conserved regions among the HRV serotypes which map to important target sites of the virus. The cellular receptor utilized in the attachment of HRVs to susceptible cells represents such a discovery. The data presented clearly demonstrate that the vast majority (89%) of HRV serotypes uses a single cellular receptor for entry into susceptible cells. This was shown by reciprocal competition binding assays (1, 12) and by isolation of a mouse monoclonal antibody capable of blocking infection of HeLa cells by the major group of HRVs.
Three criteria were used to prove that the receptor mono- The receptor antibody showed a high degree of avidity for the receptor site on HeLa cells. This was evident in the instantaneous binding of antibody to the receptor. In addition, the receptor antibody had the capability of physically displacing HRV virions from receptors in which they were previously bound (Fig. 2) . Perhaps the greatest evidence of the receptor antibody specificity and affinity for the HRV receptor was demonstrated by experiments where antibody blockage of the receptor was challenged by 109 PFU of virus.
In these experiments, not a single viral plaque could form. This result strongly suggests that the receptor blockage is not the result of a steric hindrance but is due instead to direct competition binding of the antibody to the viral attachment site on cells.
Subsequent experiments in which the receptor antibody was added at various times after viral eclipse failed to select for viral mutants. Although no direct mutagenesis has been tried, it is apparent that the major group of HRVs cannot easily mutate around the attachment block. The viral attachment site on the viral capsid may involve the spatial arrangement of all four of the viral structural proteins (VP1, VP2, VP3, and VP4). Replacement of one or two amino acids in any one structural gene may not be sufficient to change the binding specificity of the virus. Multiple amino acid changes would probably affect the structural conformation and stability of the capsid and, therefore, result in a lethal mutation.
The plaquing assays clearly demonstrate that HRV entry into susceptible cells is completely restricted to receptormediated attachment. There is absolutely no indication that HRVs could spread from cell to cell via a secondary route.
The normal functional role of the major HRV receptor remains unknown. In preliminary experiments, exposure of sparsely planted HeLa cell monolayers to a 1,000-fold excess of receptor antibody had no obvious effect on cell morphology or cell number over a 6-day period, which represented over six cell doublings (unpublished data). This appears to indicate that this cellular receptor is of minor importance for cell growth and division in cell culture. However, the finding of the HRV receptor on numerous human cells suggests that it must play some role in vivo. In conclusion, the receptor antibody has illuminated a new target area for control of HRVs and may represent a novel approach in controlling viral infection.
